High-affinity antibodies of specific isotypes are essential protections against a vast diversity of pathogens. Antigenspecific responses often involve generation of germinal centers (GCs) within secondary lymphoid tissues that create a unique environment in which B cells expressing the highest-affinity B-cell receptors capture native antigens from follicular dendritic cells and present them to cognate follicular helper T (T FH ) cells. 1, 2 Subsequent B-cell proliferation occurs with simultaneous expression of activation-induced cytidine deaminase (AID), which mediates somatic hypermutation (SHM) and class-switch recombination (CSR), leading to affinity-matured isotypeswitched antibodies and class-switched memory B cells. Immunocompromised AID-deficient mice and human subjects do not generate mutated, high-affinity antibodies and exhibit hyperplastic GCs and increased frequencies of circulating follicular helper T (cT FH ) cells and systemic cytokines that might interfere with tolerance and promote autoantibody production. 3, 4 It remains to be determined whether similar GC physiopathology might apply to other primary immunodeficiencies.
Common variable immunodeficiency (CVID) encompasses a heterogeneous group of primary antibody deficiency disorders. 5 Patients with CVID have decreased serum antibody concentrations, From poorly protective vaccine titers, and low isotype-switched B-cell frequencies. 5, 6 Paradoxically, autoantibodies, including selfreactive IgGs, can be detected in plasma of patients with CVID, 7 and approximately 20% experience autoimmune cytopenias (AICs) mediated by autoantibodies targeting either erythrocytes (autoimmune hemolytic anemia), platelets (immune thrombocytopenia [ITP]), or both (Evans syndrome). 5 It is unknown why some patients with CVID generate autoantibodies to hematopoietic self-antigens (CVID1AIC), whereas others do not (CVID2AIC) and whether this could be related to alterations in GC responses.
We report that excisional lymph node biopsy specimens from patients with CVID1AIC display irregularly shaped and hyperplastic GCs, whereas GC structures are scarce, small, and circular in patients with CVID2AIC. Despite large GCs, patients with CVID1AIC harbor fewer isotype-switched B cells with poorly mutated IgG transcripts enriched in autoreactive VH4-34-expressing clones that also recognize commensal bacteria, 8 thereby suggesting that CVID-associated autoimmunity can be triggered by failed containment of mucosal microbiota.
METHODS Patients
We obtained peripheral blood samples from 44 patients with CVID1AIC and CVID2AIC (see Table E1 in this article's Online Repository at www.jacionline. org). Each patient met 1999 Pan-American Group for Immunodeficiency CVID diagnostic criteria and was receiving antibody replacement therapy but not immunosuppressive medications at the time of enrollment. The average age of enrolled patients with CVID1AIC was 37.1 years (range, 7-68 years), and 48% were male. The average age of enrolled patients with CVID2AIC was 38.5 years (range, 10-67 years), and 35% were male. For purposes of comparison, we also obtained peripheral blood samples from 12 immunocompetent patients with ITP. The group's average age was 19.9 years (range, 8-42 years), and 40% were male. We also obtained plasma samples from 6 AID-deficient patients (average age, 30.4 years [range, 4-60 years; 50% male). Finally, we analyzed peripheral blood samples from 43 related and unrelated healthy donors (HDs) with a mean age of 37.2 years (range, 8-59 years); 41.6% were male.
Patient excisional lymph node biopsy specimens were identified based on review of our CVID cohort's medical records. Fourteen of 18 patients carried a CVID diagnosis at the time of node removal. Lymph nodes from 5 patients (1 patient with CVID1AIC and 4 patients with CVID2AIC) were obtained during breast or thyroid cancer staging before initiation of chemotherapy. All analyzed staging nodes were determined to be malignancy free by a clinical pathologist.
We obtained paired node and blood samples from 14 patients with CVID. In all cases node excision preceded blood sample donation. The mean duration between excision and phlebotomy was 51.9 months (range, 3 months to 14 years). In addition, lymph nodes were obtained from 4 patients who did not donate blood samples. One was an autopsy specimen, another was excised from a patient before hematopoietic stem cell transplantation, and 2 patients did not consent to phlebotomy. Lymph nodes from age-matched control subjects and patients with bacterial lymphadenitis were identified from available clinical pathology cases at Yale New Haven Hospital and the Children's Hospital of Philadelphia. Study protocols were approved by the institutional review boards of Yale University, Mount Sinai, the Children's Hospital of Philadelphia, and the University of Pennsylvania.
Cell staining and sorting, cDNA, RT-PCR, and VH sequence analyses Mononuclear cells were isolated from peripheral blood by using Ficoll density gradient centrifugation, and B cells were enriched with CD20 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). B cells were stained with anti-human CD19-Pacific Blue, anti-human CD27-peridinin-chlorophyllprotein complex (PerCP)-Cy5.5, anti-human CD21-allophycocyanin (APC), and anti-human IgG-phycoerythrin (PE; all from BioLegend, San Diego, Calif RT-PCR reactions, including primer sequences, were as described. In brief, IgG gene transcripts were amplified in 96-well plates with 2 rounds of nested PCRs using HotStar Taq DNA polymerase (Qiagen, Hilden, Germany) and 3.5 mL of cDNA as a template for the first PCR reactions and 3.5 mL of PCR1 reaction as a template for the second PCR reactions. 9 VH sequences were analyzed by using the National Center for Biotechnology Information IGBLAST software, and VH4-34 transcripts were aligned to the germline consensus VH4-34*01 sequence. We especially focused our analysis on the mutational status of the VH4-34 framework region 1 Ala-Val-Tyr (AVY) motif responsible for I/i self-antigen binding and the Asn-His-Ser (NHS) motif in the CDR2 region that modulates antibody affinity to cognate antigens. 8 
Lymph node staining and analysis
Hematoxylin and eosin-stained lymph node sections were analyzed at low power (12.53) on a DM4000B microscope (Leica Biosystems, Wetzlar, Germany) to capture the node's entire 2-dimensional area with a Spot RT/SE Slider camera (SPOT Imaging, Sterling Heights, Mich). Follicular structures were traced and scored for circularity in silico with ImageJ software (National Institutes of Health, Bethesda, Md) by using the following formula:
Lymph node follicular composition was determined by dividing the combined 2-dimensional areas of all follicular structures by the total lymph node area, excluding adipose-rich or acellular fibrous tissues. All pathologic images were reviewed by 1 or more hematopathologists. Immunohistochemical staining was performed with anti-CD21 (1:100; Dako, Glostrup, Denmark), anti-CD3 (prediluted; Ventana, Oro Valley, Ariz), anti-CD20 (1:200; Dako), and anti-BCL6 (1:50; Dako) antibodies.
In vitro regulatory T-cell suppression assay 
Flow cytometry
The following antibodies were used for flow cytometric staining: anti-CD19 APC-Cy7, anti-CD27 PerCP-Cy5.5, anti-CD21 Pacific Blue, anti-CD4 APC-Cy7, anti-CD25 PE-Cy7, PE or PE Dazzle, anti-CD127 PerCP-Cy5.5 or APC, anti-CD45RO AF-700, anti-CXCR5 Pacific Blue, anti-programmed cell death protein 1 (PD-1) PE-Cy7 (all from BioLegend), anti-CD3 eFluor 605NC (eBioscience, San Diego, Calif), and anti-IgG APC (Becton Dickinson). Intracellular staining with anti-Foxp3 Alexa Fluor 488 (eBioscience) or APC (BioLegend) was performed by using the Foxp3/Transcription Factor Staining Buffer Set (eBioscience), according to the manufacturer's instructions.
Endotoxin quantification
Endotoxin concentrations were determined in plasma samples by using the Pierce LAL chromogenic endotoxin quantification kit (Thermo Fischer).
Statistics
Data were analyzed with GraphPad Prism software (GraphPad Software, La Jolla, Calif) by using either Mann-Whitney U tests or linear regression analysis.
RESULTS

IgA deficiency and endotoxemia correlate with AIC development in patients with CVID
To determine what humoral alterations promote CVID1AIC, we analyzed peripheral B cells from 26 patients with CVID1AIC
and compared them with counterparts from 18 age-matched patients with CVID2AIC and 43 HD control subjects. The CVID1AIC group included 8 patients with Evans syndrome, 2 patients with autoimmune hemolytic anemia, and 16 patients with ITP, whereas 8 of 18 patients with CVID2AIC experienced other noncytopenic inflammatory diseases (see Table E1 ). The majority of enrolled patients with CVID lacked a molecular diagnosis, although some pathologic mutations in CVID-associated genes, including CTLA4, NFKB1, and TNFRSF13B, were identified mostly within the CVID1AIC group (see Table E1 ). Our CVID1AIC cohort displayed increased frequencies of CD19 hi CD21 2/lo B cells compared with patients with CVID2AIC (25.0% vs 3.8%, P <.0001; see Fig E1 in this article's Online Repository at www.jacionline.org). This B-cell subset, which was reported to be hyporesponsive in vitro, is enriched in autoreactive clones and predicts the development of AICs and splenomegaly in group Ia CVID, a patient subset defined by the Freiburg classification criteria. 6, 10, 11 In addition, we found more severely decreased CD27 1
IgG
1 memory B-cell frequencies in patients with CVID1AIC (on average, 0.6% of total B cells) compared with patients with CVID2AIC (2.8%) and HDs (5.4%; P < .01 and P < .0001, respectively; Fig 1, A and B) . IgA 1 B cells were also consistently scarce in patients with CVID1AIC, averaging only 0.3% of total B cells (P < .0001 vs control subjects), whereas patients with CVID2AIC had average frequencies similar to those of age-matched control subjects (3.4% vs 4.4%; Fig 1, A and B) .
Patients with CVID1AIC were uniformly IgA deficient, with an average serum concentration of 4.8 mg/dL, whereas the average concentration in patients with CVID2AIC was significantly greater (50.8 mg/dL, P < .001; Fig 1, C) . Because IgA antibodies contain commensal microbiota within the intestinal lumen and at other mucosal sites, 12 we tested whether patients with CVID1AIC with the lowest serum IgA concentrations and (Fig 1, C) and plasma endotoxin (Fig 1, D) concentrations are shown. Dark bars represent average group values. Statistically significant differences are indicated as follows: *P < .05, ***P < .001, and ****P < .0001, Mann-Whitney U test. n.s., Not significant.
circulating IgA 1 memory B-cell frequencies displayed bacterial endotoxins in their blood. Indeed, we found significantly increased endotoxin concentrations in the plasma of patients with CVID1AIC, which averaged 482 EU/mL and showed a concentration range similar to those in AID-deficient patients with undetectable serum IgA. Patients with CVID2AIC had endotoxin levels similar to those in HDs (198 EU/mL vs 133 EU/mL ; Fig 1, D) . We conclude that scarce IgA 1 B cells, low serum IgA concentrations, and endotoxemia specifically correlate with AIC development in patients with CVID.
1 B cells from patients with CVID1AIC express nontolerized VH4-34-encoded antibodies reported to recognize the hematopoietic I/i self-antigen and commensal bacteria Because patients with CVID1AIC had severely decreased class-switched memory B cells and resembled patients deficient for AID, which mediates CSR and SHM, we analyzed SHM frequencies in single IgG 1 B cells isolated from 6 patients with CVID1AIC, 6 patients with CVID2AIC, and 12 age-matched HDs (see Tables E2-E15 in this article's Online Repository at www.jacionline.org). As previously reported by others, we found that patients with CVID generally displayed lower SHM frequencies in heavy chain variable regions (VH) than control subjects (Fig 2, A) . 13, 14 IgG VH transcripts from patients with CVID1AIC showed the least SHM both when averaged by subject and in pooled sequences, with an average of only 7.5 mutations per VH segment compared to 15.1 mutations for patients with CVID2AIC and 18.6 mutations for HDs (patients with CVID1AIC vs patients with CVID2AIC, P < .0001; patients with CVID1AIC vs HDs, P < .0001; Fig 2, A) .
We also analyzed our cohort's IgG 1 B-cell VH repertoires and found VH3 gene segments to be most used, followed by VH4 segments, with a VH3/VH4 use ratio of 2.5:1 in both the HD and CVID-AIC groups (Fig 2, B) . 8, 15 In contrast, CVID1AIC IgG 1 B cells favored VH4 gene segment use with a VH3/VH4 ratio of 1:1 (Fig 2, B) . This difference was driven by increased use of the VH4-34 gene segment identified in 9.9% of CVID1AIC IgG transcripts, whereas VH4-34 gene segments were rarely found in HD and CVID2AIC counterparts (Fig 2, C, tive to germline IGHV4-34*01 (top). Identity to germline is denoted by a dash, and substituted residues are indicated in black unless within the critical AVY or NHS motifs (gray columns), where text color is red or green, respectively. Substitutions within both motifs are indicated in purple. E, Pie charts represent proportions of pooled transcripts in HDs and patients with CVID1AIC with AVY and/or NHS substitutions. Statistically significant differences are indicated as follows: **P < .01, ***P < .001, and ****P < .0001, Mann-Whitney U tests.
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Asn-X-Ser (NHS) located in CDR2, modulates antibody/antigen avidity. 18 VH4-34-encoded IgG antibodies also often recognize commensal bacteria when AVY and NHS motifs are unmutated. 8 To determine how SHM differentially modifies these motifs in HDs versus patients with CVID1AIC, we aligned VH4-34 IgG transcripts with the germline consensus VH4-34*01 sequence (Fig 2, D) . Although HD VH4-34 IgG transcripts displayed nonsynonymous mutations in 64.6% of AVY motifs and 76.4% of NHS motifs, we identified these mutations in only 14.2% of AVY motifs and 28.4% of NHS motifs in VH4-34-expressing B cells from patients with CVID1AIC, who therefore appear to have undergone systemic IgG responses targeting mucosal microbiota (Fig 2, D and E) . Hence AIC development correlates with the presence of VH4-34-expressing IgG 1 B cells with unmutated AVY and NHS motifs that likely recognize both I/i self-antigen and translocated commensal bacteria.
Hyperplastic and irregularly shaped GC responses specifically correlate with patients with CVID1AIC
AID deficiency-associated loss of SHM results in hyperplastic GC responses caused by sustained antigenic B-cell activation in the absence of competitive, mutated, high-affinity antibodies. 3, 4 To determine whether severely decreased SHM in patients with CVID1AIC affect their GC responses, we visualized GCs in situ through analysis of rare excisional lymph node biopsy specimens from 18 patients with CVID, 14 of whom donated blood samples for memory B-cell analyses. In total, 24 malignancyfree lymph nodes from patients with CVID, which were removed to evaluate lymphadenopathy or for cancer staging before chemotherapy, were analyzed. For comparison, we also obtained malignancy-free control axillary lymph nodes from 4 immunocompetent patients (28-43 years old). Hematoxylin and eosinstained control lymph nodes displayed distinct and well-spaced GCs comprising approximately 5% (range, 1.6% to 9.5%) of a node's cellular area (Fig 3, A and B) . These structures were scarcer in nodes from patients with CVID2AIC, occupying only 2% of the surface area (range, 0.2% to 1.9%; P <.01; Fig 3, A and B , and see Fig E3 in this article's Online Repository at www.jacionline.org). In contrast, GCs from patients with CVID1AIC were hyperplastic, covering an average of 32.9% (range, 18.5% to 44.4%) of node area (P < .001; Fig 3, A and B , and see Fig E4 in this article's Online Repository at www.jacionline.org).
In addition, in silico 2-dimensional scoring of control node GC shape generated an average circularity quotient (CQ) of 0.92 (range, 0.87-0.98), whereas a perfect circle would generate a CVID+AIC Y28 CVID+AIC Y45 FIG 3 . Asymmetric enlarged GCs predominate in lymph nodes from patients with CVID1AIC. A, Hematoxylin and eosin-stained axillary lymph node biopsy specimens from a representative immunocompetent 43-year-old woman (control subject), 2 patients with CVID2AIC, and 3 patients with CVID1AIC. GCs are outlined with white dashed lines. Original magnification 312.5. B and C, Percentages of each lymph node's cellular 2-dimensional surface comprised by GCs (Fig 3, B) and each GC's CQ (Fig 3, C) are represented for control subjects and patients. Statistically significant differences are indicated as follows: *P < .05 and ****P < .0001, Mann-Whitney U tests.
CQ of 1 (Fig 3, C) . CVID-AIC nodes also displayed circularshaped GCs (average CQ, 0.91; range, 0.88-0.96), whereas irregularly shaped GCs were common in CVID1AIC nodes, as shown by their reduced CQ score (0.67; range, 0.09-0.9; P < .0001 for both comparisons; Fig 3, C) . Many GCs from patients with CVID1AIC formed highly complex shapes potentially, suggesting coalescence of multiple GC reactions, yet immunohistochemical staining of these structures for CD20, CD3, BCL6, and CD21 suggested conventional GC cellular organization (see Fig E5 in this article's Online Repository at www.jacionline.org). Despite differences in age, lymph nodes from children with CVID1AIC (n 5 1, 7 years old) and adolescents with CVID1AIC (n 5 2, 14 and 15 years old) appeared histologically similar to nodes from adults with CVID1AIC and quite dissimilar from agematched control nodes.
Because GCs enlarge in response to infection, we also obtained 3 reactive lymph nodes from immunocompetent patients with cervical or axillary bacterial lymphadenitis to compare with lymph nodes from patients with CVID1AIC. Indeed, bacterial lymphadenitis resulted in numerous larger GCs comprising a greater average percentage of node cross-sectional area than GCs in control nodes (19.6% vs 5%, P <.05; see Fig E6, A and B, in this article's Online Repository at www.jacionline.org). However, unlike many GCs from patients with CVID1AIC, these structures remained uniformly circular (average CQ score, 0.94; range, 0.86-0.97; see Fig E6, C) . We conclude that patients with CVID1AIC have hyperplastic GCs with irregular shapes inconsistent with typical lymphadenitis, whereas patients with CVID2AIC demonstrate weak follicular responses.
Expanded cT FH cells combined with a dearth of Treg cells predict follicular hyperplasia and AICs in patients with CVID
Hyperplastic GC reactions in AID-deficient patients correlate with increased numbers of CD4
1
CXCR5
1 PD-1 hi cT FH cells, which normally promote B-cell survival, proliferation, and SHM.
3 Previously, we reported that patients with CVID with heterozygous TNFRSF13B mutations and many with AICs displayed increased cT FH frequencies, but we did not assess whether this feature was associated with AICs or dysregulated GC reactions. 7, 19 Therefore we compared cT FH frequencies in patients with CVID1AIC and patients with CVID2AIC, immunocompetent patients with ITP, and HDs. We found cT FH frequencies were significantly increased in patients with CVID1AIC (range, 10.2% to 32.9%) compared with those in patients with CVID2AIC, patients with ITP without CVID, and HDs (1.3% to 9.6%, P < .0001; Fig 4, A  and B) . In addition, although Treg cells represented around 5% of CD4
1 T compartments from HDs and patients with patients with CVID2AIC, and 7 patients with CVID1AIC are represented. Statistically significant differences are indicated as follows: *P < .05, **P < .01, ***P < .001, and ****P < .0001, Mann-Whitney U tests or linear regression analysis.
ITP, Treg cell frequencies were significantly decreased in patients with CVID, especially with AICs (Fig 4, B) . Bivariate analysis of cT FH and Treg cell frequencies from HDs, immunocompetent patients with ITP, and patients with CVID revealed an inverse and linear relationship between these variables (R 2 5 0.31, P < .0001), with values assigned to patients with CVID1AIC forming a unique cluster defined by cT FH cell abundance and Treg cell paucity (Fig 4, C) . Moreover, CD4
1
CD25
hi CD127 lo Treg cells from patients with CVID1AIC did not suppress the in vitro proliferation of HD Tresp cells, whereas Treg cells from patients with CVID2AIC showed intermediate suppressive capacities (Fig  4, D and E) . Thus AIC development in patients with CVID correlates with an expanded cT FH cell compartment combined with quantitative and qualitative Treg cell alterations.
DISCUSSION
We show here that AIC development in patients with CVID is associated with hyperplastic and irregularly shaped GCs, which correlate with reduced IgA levels, endotoxemia, increased cT FH cell frequencies, dearth of Treg cell, and severely reduced isotype-switched memory B-cell compartments containing decreased SHM and enriched in nontolerized autoreactive VH4-34-expressing IgG 1 clones. Several of these features were identified previously in AID-deficient patients and in patients with CVID with lymphadenopathy/tonsillar hyperplasia and are likely linked to altered SHM. 3, 7, 20, 21 Abrogated and decreased SHM caused by either inborn AID deficiency or poor AID induction previously described in B cells from patients with CVID, 22 respectively, diminishes generation of high-affinity antibodies that normally constrain GC reactions by either competing with GC B cells for binding sites on specific follicular dendritic cell2provided antigens and/or by forming inhibitory immune complexes that co-crosslink B-cell receptors and inhibitory FcgRIIb receptors. 2, 3, 23 Hence prolonged B-cell activation when SHM is either impaired or decreased likely favors T FH cell expansion and secretion of IL-4, IL-21, and inflammatory cytokines that can alter Treg cell function. 3, 7 Decreased SHM combined with defective CSR also limits anticommensal IgA production that might result in failed mucosal microbiota containment, especially in the gut, further inducing systemic immune responses involving GCs. 8 In agreement with this hypothesis, high plasma levels of endotoxins were reported previously in patients with CVID before IgG replacement therapy. 24 Among our IgG-replete cohort, we found increased bacterial endotoxin plasma concentrations specifically in IgA-deficient patients with CVID1AIC who also possessed VH4-34 1
IgG
1 B cells with unmutated AVY and NHS motifs, which have been reported recently to recognize commensal bacteria. 8 Because these AVY-and NHS-unmutated VH4-34
1 IgG clones are also autoreactive and recognize the I/i self-antigens expressed on the surfaces of erythrocytes and other hematopoietic cells types, [16] [17] [18] we propose that these antibodies can contribute to the destruction of red blood cells in patients with CVID with hemolytic anemia and perhaps platelets in those with thrombocytopenia, thereby potentially mediating AICs.
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